Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Aquinox Pharmaceuticals Inc    AQXP

AQUINOX PHARMACEUTICALS INC (AQXP)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
2.7(c) 2.71(c) 2.65(c) 2.53(c) 2.73 Last
507 891 700 378 963 694 711 361 425 500 Volume
-1.10% +0.37% -2.21% -4.53% +7.91% Change
More quotes
Financials (USD)
Sales 2018 6,25 M
EBIT 2018 -46,5 M
Net income 2018 -46,0 M
Debt 2018 -
Yield 2018 -
Sales 2019 -
EBIT 2019 -56,9 M
Net income 2019 -56,5 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 9,97x
Capi. / Sales2019 0
Capitalization 62,3 M
More Financials
Company
Aquinox Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company.It discovers and develops targeted therapeutics for inflammation and immuno-oncology.It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling... 
Sector
Pharmaceuticals
Calendar
08/08Earnings Release
More about the company
Surperformance© ratings of Aquinox Pharmaceuticals In
Trading Rating : Investor Rating : -
More Ratings
Latest news on AQUINOX PHARMACEUTICALS IN
07/11AQUINOX PHARMACEUTICALS : After rosiptor`s phase 3 rout, Aquinox to cut staff by..
AQ
07/09AQUINOX PHARMACEUTICALS, INC : Costs Associated with Exit or Disposal Activities..
AQ
07/02AQUINOX PHARMACEUTICALS : Announces Topline Results of Phase 3 LEADERSHIP 301 Cl..
AQ
06/28AQUINOX PHARMACEUTICALS : Pharma (AQXP) Phase 3 LEADERSHIP 301 Clinical Trial in..
AQ
06/28TODAY’S RESEARCH REPORTS ON STOCKS T : Aquinox Pharmaceuticals and Summit Therap..
AC
06/28AQUINOX PHARMACEUTICALS : Announces Topline Results of Phase 3 LEADERSHIP 301 Cl..
AQ
06/28AQUINOX PHARMACEUTICALS : With the ink on their $25M Astellas deal still drying,..
AQ
06/27AQUINOX PHARMACEUTICALS, INC : Other Events, Financial Statements and Exhibits (..
AQ
06/27Aquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in..
GL
06/13AQUINOX PHARMACEUTICALS : Announces Initiation of ProShip Phase 2 Proof-of-Conce..
AQ
More news
Sector news : Pharmaceuticals - NEC
07/16Startup Producing Cell-Grown Meat Raises New Funding
DJ
07/16J&J'S JANSSEN : Credence Trial of Invokana Being Stopped Early for Positive Effi..
DJ
07/16ASTRAZENECA : Swedish Business Appoints New CEO
DJ
07/16Indivior's shares soar 33 percent after U.S. court blocks sale of rival gener..
RE
07/16SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
07/15Why Boaty McBoatface had to be torpedoed | David Mitchell
24
07/15Why Boaty McBoatface had to be torpedoed | David Mitchell
3
07/13Tomorrow’s birthdays: Conor McGregor (30), Dan Reynolds (31), David Mitchell..
1
07/10$AQXP Aquinox Pharmaceuticals shares slump after restructuring plan disclosed.. 
07/10Premarket Losers as of 9:05 am (07/10/2018)  
More tweets
Qtime:212
News from SeekingAlpha
07/10PREMARKET LOSERS AS OF 9 : 05 am (07/10/2018) 
07/09Achillion Pharmaceuticals - Biotech Gold For The Price Of Dirt 
07/03Aquinox Tumbles 82% On Failed Late-Stage Study, But Proof-Of-Concept Trial Mi.. 
06/29YOUR DAILY PHARMA SCOOP : FDA Approval For Array, Edge Zooms, Summit Nosedives 
06/28Aquinox Pharma (AQXP) Targeted Therapeutics For Inflammatory Disease - Slides.. 
Chart AQUINOX PHARMACEUTICALS IN
Duration : Period :
Aquinox Pharmaceuticals In Technical Analysis Chart | AQXP | US03842B1017 | 4-Traders
Technical analysis trends AQUINOX PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 14,0 $
Spread / Average Target 428%
EPS Revisions
Managers
NameTitle
David J. Main Chairman, President & Chief Executive Officer
Lloyd Mackenzie Chief Operating Officer
Kamran Alam Chief Financial Officer, Secretary & VP
Barbara Troupin Chief Medical Officer & VP-Regulatory Affairs
Daniel J. Levitt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AQUINOX PHARMACEUTICALS INC-78.49%63
JOHNSON & JOHNSON-9.87%337 763
PFIZER3.62%219 534
NOVARTIS-3.93%201 464
ROCHE HOLDING LTD.-5.60%200 973
MERCK AND COMPANY11.76%169 193